One patient achieved a complete response, and 10 had a partial response. Enfortumab vedotin may be a treatment option for patients with advanced head and neck cancer that is not amenable to ...

Introduction: Enfortumab vedotin (EV) and Erdafitinib are effective therapeutic drugs for bladder cancer patients following post-chemotherapy and immunotherapy. This study assessed adverse drug ...

We report two cases of patients with metastatic urothelial cancer who initially responded to enfortumab vedotin (EV) before developing leptomeningeal metastases. Case presentation: Case 1: A 55 ...

In an interview with Targeted Oncology, Sophia Kamran, MD, discussed the effectiveness of trimodality therapy as well as other novel therapeutics in patients with bladder cancer. Thomas Powles, MD, ...

to accurately model a patient's response to CAR T cell therapy in real time. The organoid's response to therapy mirrored the response of the actual tumor in the patient's brain. That is ...

to accurately model a patient's response to CAR T cell therapy in real time. The organoid's response to ... Nov. 12, 2024 — Glioblastoma is the most common kind of malignant brain tumor in adults.

Help may come from a mysterious source. Venus coordinating with Jupiter can send you gifts out of thin air. Not expecting this offering? Don’t think about it too much. You don’t have to make ...

A small, more affordable Model Y is coming to the U.S. in 2025, says an automobile intelligence firm. This comes after a series of statements by Tesla executives about “affordable” models ...